NIH K38 Transition Scholar
Dr. Vaios started working on this project when he was a radiation oncology resident. He transitioned to a faculty appointment after being awarded an NIH K38 grant that is focused on development of a non-invasive biomarker that could improve diagnosis, risk assessment, and treatment monitoring. His study used cell-free DNA (cfDNA) methylation profiling as a novel biomarker for glioblastoma, leveraging blood samples from the Phase II VERTU clinical trial. In this project we will assess whether cfDNA methylation aligns with tumor DNA patterns, correlates with survival, and distinguishes pseudoprogression from recurrence. This approach could offer new diagnostic and monitoring tools for glioblastoma, aiding in treatment and clinical trial design.